$EVAX
$3.30
+$0.18 (5.9%)
Evaxion A/S
evaxion.aiEvaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Financial Snapshot
Revenue
TTM
$7.492M
Gross Margin
Last 4 Quarters
N/A
Net Income
TTM
-$8.658M
Current Assets
2026 Q2
$15.86M
Current Liabilities
2026 Q2
$3.133M
Current Ratio
2026 Q2
506.16%
Total Assets
2026 Q2
$19.38M
Total Liabilities
2026 Q2
$9.849M
Book Value
2026 Q2
9.531M
Cash
Last 4 Quarters
N/A
P/E
Last 4 Quarters
N/A
Free Cash Flow
Last 4 Quarters
N/A
Loading...
